174 related articles for article (PubMed ID: 35545128)
1. FOXO3a in cancer drug resistance.
Liu Y; Wang Y; Li X; Jia Y; Wang J; Ao X
Cancer Lett; 2022 Aug; 540():215724. PubMed ID: 35545128
[TBL] [Abstract][Full Text] [Related]
2. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance.
Gomes AR; Zhao F; Lam EW
Chin J Cancer; 2013 Jul; 32(7):365-70. PubMed ID: 23706767
[TBL] [Abstract][Full Text] [Related]
3. Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.
Nestal de Moraes G; Bella L; Zona S; Burton MJ; Lam EW
Curr Drug Targets; 2016; 17(2):164-77. PubMed ID: 25418858
[TBL] [Abstract][Full Text] [Related]
4. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
Zhao F; Lam EW
Front Med; 2012 Dec; 6(4):376-80. PubMed ID: 23124885
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.
Aldonza MB; Hong JY; Lee SK
Exp Mol Med; 2017 Jan; 49(1):e286. PubMed ID: 28104912
[TBL] [Abstract][Full Text] [Related]
6. Foxo3a expression and acetylation regulate cancer cell growth and sensitivity to cisplatin.
Shiota M; Yokomizo A; Kashiwagi E; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Seki N; Naito S
Cancer Sci; 2010 May; 101(5):1177-85. PubMed ID: 20210796
[TBL] [Abstract][Full Text] [Related]
7. Potent FOXO3a Activators from Biologically Active Compound Library for Cancer Therapeutics: An in silico Approach.
Manoharan S; Vedagiri H; Perumal E
Appl Biochem Biotechnol; 2023 Aug; 195(8):4995-5018. PubMed ID: 37017892
[TBL] [Abstract][Full Text] [Related]
8. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.
Liu H; Yin J; Wang H; Jiang G; Deng M; Zhang G; Bu X; Cai S; Du J; He Z
Cell Signal; 2015 Mar; 27(3):510-8. PubMed ID: 25578861
[TBL] [Abstract][Full Text] [Related]
9. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
10. Targeted Regulation of FoxO3a by miR-372 to Mediate Gastric Carcinoma Cell Apoptosis and DDP Drug Resistance.
Wang C; Wang C; Qiu C; Su Z
Cancer Biother Radiopharm; 2020 Dec; 35(10):753-759. PubMed ID: 32379491
[No Abstract] [Full Text] [Related]
11. Critical role of FOXO3a in carcinogenesis.
Liu Y; Ao X; Ding W; Ponnusamy M; Wu W; Hao X; Yu W; Wang Y; Li P; Wang J
Mol Cancer; 2018 Jul; 17(1):104. PubMed ID: 30045773
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2.
Li J; Yang R; Dong Y; Chen M; Wang Y; Wang G
J Exp Clin Cancer Res; 2019 Jan; 38(1):38. PubMed ID: 30691517
[TBL] [Abstract][Full Text] [Related]
13. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
Sun T; Zhang J; Deng B; Fan X; Long T; Jin H; Tao S; Kang P; Tan Q
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1348-1359. PubMed ID: 33167006
[TBL] [Abstract][Full Text] [Related]
14. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract][Full Text] [Related]
15. FOXO3a functions as a transcriptional and co-transcriptional splicing regulator in vascular endothelial cell lines.
Abudureyimu S; He C; Xie W; Chen Z; Airikenjiang H; Abulaiti D; Cao Y; Qiu H; Gao Y
Gene; 2024 Apr; 904():148221. PubMed ID: 38286271
[TBL] [Abstract][Full Text] [Related]
16. FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin L.
Yu S; Yu Y; Zhang W; Yuan W; Zhao N; Li Q; Cui Y; Wang Y; Li W; Sun Y; Liu T
Oncotarget; 2016 Jun; 7(23):34773-84. PubMed ID: 27127880
[TBL] [Abstract][Full Text] [Related]
17. [FOXO3a signaling pathway in prostate cancer: Progress in studies].
Tao Y; Li LL; Liu SH; Hong M
Zhonghua Nan Ke Xue; 2020 Aug; 26(8):745-750. PubMed ID: 33377739
[TBL] [Abstract][Full Text] [Related]
18. Forkhead transcription factor FOXO3a protein activates nuclear factor κB through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation.
Li Z; Zhang H; Chen Y; Fan L; Fang J
J Biol Chem; 2012 May; 287(21):17737-17745. PubMed ID: 22474286
[TBL] [Abstract][Full Text] [Related]
19. FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer.
Lu M; Chen X; Xiao J; Xiang J; Yang L; Chen D
Arch Med Res; 2018 Feb; 49(2):84-88. PubMed ID: 29716743
[TBL] [Abstract][Full Text] [Related]
20. MiR-155 targeting FoxO3a regulates oral cancer cell proliferation, apoptosis, and DDP resistance through targeting FoxO3a.
Li X; Liu K; Zhou W; Jiang Z
Cancer Biomark; 2020; 27(1):105-111. PubMed ID: 31771044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
